Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0X3TI
|
|||
| Former ID |
DNCL002922
|
|||
| Drug Name |
SRT3025
|
|||
| Indication | Type-2 diabetes [ICD-11: 5A11; ICD-9: 250] | Phase 1 | [1] | |
| Company |
Sirtris
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C31H31N5O2S2
|
|||
| Canonical SMILES |
COCCCC1=C(N=C(S1)C2=CC=CC=C2)C(=O)NC3=CC=CC=C3C4=NC5=C(S4)N=CC(=C5)CN6CCCC6
|
|||
| InChI |
1S/C31H31N5O2S2/c1-38-17-9-14-26-27(35-29(39-26)22-10-3-2-4-11-22)28(37)33-24-13-6-5-12-23(24)30-34-25-18-21(19-32-31(25)40-30)20-36-15-7-8-16-36/h2-6,10-13,18-19H,7-9,14-17,20H2,1H3,(H,33,37)
|
|||
| InChIKey |
MRRXPMZNBRXCPZ-UHFFFAOYSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | NAD-dependent deacetylase sirtuin-1 (SIRT1) | Target Info | Modulator | [2] |
| KEGG Pathway | FoxO signaling pathway | |||
| AMPK signaling pathway | ||||
| Glucagon signaling pathway | ||||
| Amphetamine addiction | ||||
| MicroRNAs in cancer | ||||
| Panther Pathway | p53 pathway | |||
| Pathway Interaction Database | p73 transcription factor network | |||
| Signaling events mediated by HDAC Class III | ||||
| E2F transcription factor network | ||||
| HIF-2-alpha transcription factor network | ||||
| Signaling events mediated by HDAC Class I | ||||
| FoxO family signaling | ||||
| Regulation of Androgen receptor activity | ||||
| Regulation of retinoblastoma protein | ||||
| Reactome | RORA activates gene expression | |||
| Regulation of HSF1-mediated heat shock response | ||||
| Circadian Clock | ||||
| WikiPathways | Integrated Pancreatic Cancer Pathway | |||
| SREBF and miR33 in cholesterol and lipid homeostasis | ||||
| Integrated Breast Cancer Pathway | ||||
| SREBP signalling | ||||
| Androgen receptor signaling pathway | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01340911) A Study in Healthy Male Volunteers to Investigate Different Doses of a New Drug for the Treatment of Metabolic Diseases. U.S. National Institutes of Health. | |||
| REF 2 | The Sirt1 Activators SRT2183 and SRT3025 Inhibit RANKL-Induced Osteoclastogenesis in Bone Marrow-Derived Macrophages and Down-Regulate Sirt3 in Sirt1 Null Cells. PLoS One. 2015 Jul 30;10(7):e0134391. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.